Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€54.50

€54.50

-0.920%
-0.5
-0.920%
€70.00
 
28.03.24 / Tradegate WKN: A2JAAW / Symbol: APLS / Name: Apellis Pharmaceuticals / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Apellis Pharmaceuticals Stock

The price for the Apellis Pharmaceuticals stock decreased slightly today. Compared to yesterday there is a change of -€0.500 (-0.920%).
Currently there is a rather positive sentiment for Apellis Pharmaceuticals with 4 Buy predictions and 0 Sell predictions.
With a target price of 70 € there is a positive potential of 28.44% for Apellis Pharmaceuticals compared to the current price of 54.5 €.
So far the community has only identified positive things for Apellis Pharmaceuticals stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Apellis Pharmaceuticals in the next few years

Pros
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Apellis Pharmaceuticals vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Apellis Pharmaceuticals -0.920% - - - - - -
Gritstone Oncology Inc -6.610% -4.678% -6.857% 6.722% 31.593% -73.850% -
Rockwell Medical Inc. 1.330% 9.901% 25.121% -6.386% -12.795% -85.658% -97.163%
Innoviva Inc. 0.700% 2.899% -0.699% 36.538% -2.740% 42.000% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-01

Peering into the financial statements of a company like Apellis Pharmaceuticals, one would quickly notice that it's a company with substantial market interest, evidenced by a market capitalization in the billions. However, a glimpse reveals that the company is navigating through some challenging waters, characterized by substantial EBITDA losses and a currently inoperative P/E ratio due to negative earnings. It's not uncommon to see such financial landscapes in the pharmaceutical industry, especially within companies focusing on research and development.

The initial financial snapshot of Apellis Pharmaceuticals presents a mix of opportunities and concerns. While a high market capitalization of approximately $5.78 billion signifies strong market confidence, the absence of P/E and PEG ratios indicate a lack of profitability in the recent past. The targeted share price of $67.81 suggests optimism about the company's future prospects. That being said, negative values in profit margins and operating margins, coupled with a significant EBITDA loss, paint a picture of a company that is currently not generating profit from its operations.

The financial ratios underscore a company yet to reach profitability, with Return on Assets (ROA) and Return on Equity (ROE) being negative. However, an increase in year-over-year quarterly revenue growth hints at an expanding market share or rising demand for the company's products.